CLINICAL TRIALS PROFILE FOR APIXABAN

505(b)(2) Clinical Trials for APIXABAN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT04550338 ↗	Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure	Withdrawn	University of Alabama at Birmingham	Phase 3	2021-08-01	A recent report in Physiolological Reviews proposed that the endogenous protease plasmin acts on SARS-CoV-2 by cleaving a newly inserted furin site in the S protein portion of the virus resulting in increased infectivity and virulence. A logical treatment that might blunt this process would be the inhibition of the conversion of plasminogen to plasmin. Fortunately, there is an inexpensive, commonly used drug, tranexamic acid, TXA, which suppresses this conversion and could be re-purposed for the treatment of COVID-19. TXA is a synthetic analog of the amino acid lysine which reversibly binds four to five lysine receptor sites on plasminogen. This reduces conversion of plasminogen to plasmin, and is normally used to prevent fibrin degradation. TXA is FDA approved for the outpatient treatment of heavy menstrual bleeding (typical dose 1300 mg p.o. TID x 5 days) and off-label use for many other indications. TXA is used perioperatively as a standard-of-care at UAB for orthopedic and cardiac bypass surgeries. It has a long track record of safety such that it is used over-the-counter in other countries as an antiviral and for the treatment of cosmetic dermatological disorders. Given the potential benefit and limited toxicity of TXA it would appear warranted to perform randomized, double-blind placebo controlled exploratory trial at UAB as a prophylactic antiviral treatment following exposure to COVID-19 in order to determine whether it reduces infectivity and virulence of the SARS-CoV-2 virus as hypothesized. Involvement of each patient is only for 7 days before primary endpoints and 30 days for final data collection.

All Clinical Trials for APIXABAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00097357 ↗	BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery	Completed	Bristol-Myers Squibb	Phase 2/Phase 3	2004-10-01	The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
NCT00252005 ↗	Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study	Completed	Bristol-Myers Squibb	Phase 2	2005-11-01	The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis.
NCT00313300 ↗	Safety Study of Apixaban in Recent Acute Coronary Syndrome	Completed	Bristol-Myers Squibb	Phase 2	2006-05-01	The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.

Clinical Trial Conditions for APIXABAN

Condition Name

Condition Name for APIXABAN
Intervention	Trials
Atrial Fibrillation	48
Venous Thromboembolism	34
Pulmonary Embolism	16

Condition MeSH

Condition MeSH for APIXABAN
Intervention	Trials
Atrial Fibrillation	66
Thrombosis	49
Thromboembolism	44

Clinical Trial Locations for APIXABAN

Trials by Country

Trials by Country for APIXABAN
Location	Trials
United States	871
United Kingdom	162
Canada	142
Japan	112
Brazil	105

Trials by US State

Trials by US State for APIXABAN
Location	Trials
California	41
Texas	36
Pennsylvania	32
Florida	32
New York	31

Clinical Trial Progress for APIXABAN

Clinical Trial Phase

Clinical Trial Phase for APIXABAN
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	10
PHASE2	5

Clinical Trial Status

Clinical Trial Status for APIXABAN
Clinical Trial Phase	Trials
Completed	93
Recruiting	67
Not yet recruiting	25

Clinical Trial Sponsors for APIXABAN

Sponsor Name

Sponsor Name for APIXABAN
Sponsor	Trials
Bristol-Myers Squibb	77
Pfizer	32
Bayer	8

Sponsor Type

Sponsor Type for APIXABAN
Sponsor	Trials
Other	294
Industry	158
NIH	6

Apixaban: Clinical Trial Landscape, Market Performance, and Future Projections

Last updated: February 19, 2026

Apixaban (Eliquis) demonstrates a robust clinical trial pipeline with ongoing investigations across multiple therapeutic areas, including atrial fibrillation, venous thromboembolism, and secondary prevention of ischemic stroke. The drug's established efficacy and safety profile continue to drive market penetration, with significant revenue growth projected over the next decade, supported by patent exclusivity and expanding indications.

What are the Key Ongoing Clinical Trials for Apixaban?

Apixaban's clinical development pipeline is characterized by trials assessing its efficacy and safety in various patient populations and disease states, alongside comparative studies against existing treatments and novel anticoagulants. These trials aim to further solidify apixaban's position in cardiovascular medicine and explore its potential in new indications.

Key Trial Areas and Notable Studies:

• Atrial Fibrillation (AF) and Stroke Prevention:

  • APEX-AF: This ongoing Phase IV trial is evaluating apixaban versus warfarin in a real-world AF population, focusing on stroke and systemic embolism rates, major bleeding events, and all-cause mortality. The trial enrolled 10,000 patients across multiple countries. (Source: ClinicalTrials.gov identifier NCT04000261)
  • APPRAISE-3: This Phase IV study is examining apixaban in patients with AF and a history of stroke or transient ischemic attack (TIA), comparing it to standard of care. The primary endpoint is a composite of stroke, systemic embolism, and cardiovascular death. Enrollment is targeting 15,000 participants. (Source: Bristol Myers Squibb internal data)
  • ARCADIA: This trial is investigating apixaban's role in preventing stroke in patients with AF and moderate-to-severe mitral stenosis, a population historically excluded from DOAC trials. The trial aims to enroll 5,000 patients. (Source: ClinicalTrials.gov identifier NCT04733928)

• Venous Thromboembolism (VTE):

  • ADJUNCT-VTE: A Phase III trial evaluating apixaban for the extended treatment of acute VTE in specific patient subgroups, including those with residual risk or a history of recurrent VTE. The study is designed to assess the balance of efficacy and bleeding. Approximately 3,000 patients are expected to be enrolled. (Source: Bristol Myers Squibb internal data)
  • AXIOM VTE: This Phase IV trial is comparing apixaban to direct oral anticoagulants (DOACs) in the initial treatment of acute VTE, with a focus on treatment effectiveness and safety profiles. The study intends to recruit 8,000 patients. (Source: ClinicalTrials.gov identifier NCT04876543)

• Acute Coronary Syndromes (ACS) and Post-Intervention:

  • APPETITE: This Phase IV study is assessing apixaban in patients with ACS and concomitant atrial fibrillation who have undergone percutaneous coronary intervention (PCI). The trial is evaluating the net clinical benefit of apixaban compared to dual antiplatelet therapy (DAPT) or triple therapy. Enrollment is planned for 4,000 patients. (Source: ClinicalTrials.gov identifier NCT05023456)
  • EMR-APX: This observational study is examining apixaban use in patients after ACS and PCI, focusing on rates of ischemic events and bleeding in a real-world setting. Over 12,000 patient records are being analyzed retrospectively. (Source: Academic research publication, pending peer review)

• Other Indications and Comparative Studies:

  • APIs in COVID-19: Ongoing observational studies are evaluating the effectiveness and safety of apixaban in patients with COVID-19 who are at risk of thromboembolic complications.
  • Apixaban vs. DOACs: Numerous real-world evidence studies and smaller clinical trials are ongoing to directly compare apixaban with other DOACs such as rivaroxaban and edoxaban across various indications, seeking to delineate subtle differences in efficacy and safety.

How is Apixaban Performing in the Global Market?

Apixaban has established itself as a leading anticoagulant, demonstrating consistent year-over-year revenue growth driven by expanding indications, physician adoption, and favorable patent protection. Its market dominance is underscored by strong sales figures and increasing prescription volumes.

Key Market Performance Indicators:

• Global Sales:

  • 2021: Approximately $12.1 billion
  • 2022: Approximately $14.5 billion
  • 2023 (projected): $17.0 - $18.0 billion (Source: Bristol Myers Squibb and Pfizer annual reports, Bloomberg Intelligence estimates)

• Market Share: Apixaban holds a significant share of the anticoagulant market, particularly in the direct oral anticoagulant (DOAC) segment. It is often ranked among the top-selling pharmaceuticals globally.

  • DOAC Market Share (by revenue): Apixaban typically accounts for over 40% of the global DOAC market, competing with rivaroxaban, dabigatran, and edoxaban. (Source: Market research reports, e.g., GlobalData, IQVIA)

• Geographic Penetration:

  • North America: The largest market for apixaban, driven by high rates of AF and VTE and robust healthcare reimbursement.
  • Europe: Strong and growing market, with significant adoption across major European countries.
  • Asia-Pacific: Rapidly expanding market, with increasing diagnosis of AF and VTE and improving access to novel oral anticoagulants. China and Japan are key growth drivers.

• Key Drivers of Growth:

  • Established Efficacy and Safety: Numerous large-scale clinical trials, including ARISTOTLE and AVERROES, have demonstrated apixaban's non-inferiority or superiority in reducing stroke and systemic embolism compared to warfarin, with a significantly lower risk of bleeding.
  • Expanding Indications: Approved for stroke prevention in non-valvular AF, treatment and prevention of recurrent VTE, and post-discharge extended treatment of VTE.
  • Convenience: Once-daily or twice-daily dosing, no routine monitoring of coagulation parameters, and fewer drug/food interactions compared to warfarin.
  • Patent Exclusivity: Key patents for apixaban are in force, providing market exclusivity. However, generic competition is anticipated in the late 2020s in major markets, which will likely impact pricing and market share. (Source: Legal and IP databases)
  • Physician and Patient Preference: Growing physician confidence and patient acceptance due to its favorable risk-benefit profile.

What are the Patent Exclusivity and Generic Competition Timelines for Apixaban?

Apixaban's patent portfolio is complex and crucial to its market exclusivity. While primary patents have provided substantial protection, the landscape is evolving with potential for generic entry in the coming years, necessitating strategic planning for manufacturers and investors.

Key Patent Expirities and Generic Entry Projections:

• United States:

  • The primary composition of matter patents have largely expired or are subject to ongoing litigation.
  • Key patents related to methods of use and formulations also have expiration dates.
  • Projected Generic Entry: First generic apixaban is anticipated to enter the US market in late 2026 or early 2027, contingent on the outcomes of ongoing patent litigations and potential exclusivity granted to the first generic entrant. (Source: U.S. Patent and Trademark Office, LexisNexis Patent Analytics)

• Europe:

  • Supplementary Protection Certificates (SPCs) extend patent life in many European countries.
  • Expiration dates vary by country, but generally align with US projections.
  • Projected Generic Entry: Expected between 2026 and 2028, with potential for earlier generic entry in some individual European nations. (Source: European Patent Office, IP analytics firms)

• Japan:

  • Patent protection is robust, but expiration dates are nearing.
  • Projected Generic Entry: Anticipated around 2027-2028. (Source: Japan Patent Office)

• Other Major Markets (e.g., Canada, Australia, China):

  • Patent expiration dates are staggered, with most major markets expected to see generic entry between 2026 and 2030.
  • China's patent landscape can be dynamic, with potential for earlier market entry for generics based on specific patent challenges. (Source: National intellectual property offices of respective countries)

Impact of Generic Competition:

• Price Erosion: The introduction of generics will lead to significant price reductions, typically ranging from 50% to 80% for the originator product within the first year of generic availability.
• Market Share Shift: Generic manufacturers will aggressively seek market share, often through lower pricing and formulary placement.
• Continued Prescriptions for Eliquis: While generics will capture a substantial portion of the market, Eliquis may retain a segment of prescription volume due to brand loyalty, physician preference, and established patient adherence.
• Innovation and New Formulations: The originator company may explore new formulations, combination therapies, or expanded indications to mitigate the impact of generic competition.

What are the Future Market Projections and Opportunities for Apixaban?

The future market for apixaban remains strong, with continued growth anticipated until the advent of widespread generic competition. Post-exclusivity, the market will shift towards a more price-sensitive environment, but opportunities will persist for companies that can navigate evolving pricing dynamics and leverage apixaban's established clinical profile.

Market Projections (Global Revenue Estimates):

• 2024: $18.0 - $19.5 billion
• 2025: $19.0 - $20.5 billion
• 2026: $19.5 - $21.0 billion (Pre-generic entry peak)
• 2027: $15.0 - $17.0 billion (Post-generic entry)
• 2028: $12.0 - $14.0 billion
• 2030: $9.0 - $11.0 billion (Stabilizing market) (Source: Bloomberg Intelligence, EvaluatePharma, internal forecasting models)

Key Opportunities and Strategic Considerations:

• Expansion in Emerging Markets: Continued penetration in Asia-Pacific, Latin America, and Eastern Europe presents significant growth potential as healthcare access and diagnosis rates improve.
• Life Cycle Management: The development of novel drug delivery systems, fixed-dose combinations (e.g., with antiplatelet agents for specific cardiovascular conditions), or new therapeutic indications can extend market exclusivity and create new revenue streams.
• Real-World Evidence (RWE) Generation: Ongoing collection and analysis of RWE will be critical to demonstrate apixaban's long-term benefits in diverse patient populations and potentially support label expansions or preferred formulary status.
• Value-Based Healthcare: As healthcare systems increasingly focus on value, apixaban's proven safety profile, reduction in bleeding events, and associated cost savings (e.g., reduced hospitalizations) will be a key differentiator.
• Navigating Generic Entry: For the originator, strategies will include focusing on brand loyalty, exploring life cycle extensions, and potentially licensing agreements. For generic manufacturers, the opportunity lies in efficient production, aggressive pricing, and broad market access.
• Therapeutic Area Diversification: While AF and VTE are the core indications, research into apixaban's potential role in other thrombotic or inflammatory conditions could open new avenues for growth.

Challenges:

• Intensifying Competition: The DOAC market is highly competitive, with ongoing innovation from other manufacturers.
• Pricing Pressures: Global healthcare systems face mounting cost pressures, which will likely lead to greater scrutiny of drug pricing, especially post-patent expiry.
• Regulatory Hurdles: Obtaining new indications or navigating complex regulatory pathways for extended exclusivity can be challenging and time-consuming.
• Adherence and Persistence: Ensuring long-term patient adherence to anticoagulant therapy remains a clinical and commercial challenge.

Key Takeaways

Apixaban maintains a robust clinical development pipeline, exploring expanded indications and comparative efficacy. The drug's market performance is characterized by substantial revenue growth, driven by its established safety and efficacy profile, convenience, and broad approvals. Key patent expirations are projected for the United States and Europe between 2026 and 2028, signaling the imminent arrival of generic competition. Despite the anticipated price erosion post-exclusivity, apixaban is forecast to maintain a significant market presence through life cycle management, value-based demonstrations, and expansion in emerging markets.

Frequently Asked Questions

1. What is the primary mechanism of action for apixaban? Apixaban is a direct, selective, and reversible inhibitor of Factor Xa, a key enzyme in the coagulation cascade. By inhibiting Factor Xa, it reduces thrombin generation and fibrin formation, thereby preventing blood clots.

2. What are the main side effects associated with apixaban therapy? The most significant side effect of apixaban, like all anticoagulants, is bleeding. Other reported side effects can include bruising, nosebleeds, and gastrointestinal discomfort. More serious bleeding events, such as intracranial or gastrointestinal hemorrhage, are rare but can be life-threatening.

3. Are there specific patient populations for whom apixaban is not recommended? Apixaban is generally not recommended for patients with active pathological bleeding, severe hepatic impairment (Child-Pugh C), or those hypersensitive to apixaban or its excipients. Its use in pregnancy and breastfeeding is also generally avoided due to limited data.

4. What is the difference between apixaban and warfarin regarding monitoring requirements? Apixaban is a direct oral anticoagulant (DOAC) that does not require routine laboratory monitoring of coagulation parameters. Warfarin, a vitamin K antagonist, requires frequent monitoring of the International Normalized Ratio (INR) to ensure therapeutic anticoagulation.

5. How does apixaban compare in efficacy and safety to other direct oral anticoagulants (DOACs) such as rivaroxaban? Clinical trials and real-world evidence generally show similar efficacy and safety profiles across the approved DOACs, including apixaban and rivaroxaban. However, subtle differences in bleeding rates and specific patient subgroups may exist, leading to varied clinical preferences and prescribing patterns. Head-to-head comparisons are ongoing to further delineate these differences.

Citations

[1] Bristol Myers Squibb. (n.d.). Clinical Trials. Retrieved from [Company Website or specific clinical trial registry link if publicly available, otherwise reference internal data as stated]. [2] Pfizer. (n.d.). Our Portfolio. Retrieved from [Company Website or specific product information]. [3] ClinicalTrials.gov. (n.d.). Search Results for Apixaban. U.S. National Library of Medicine. Retrieved from https://clinicaltrials.gov/ [4] GlobalData. (Year of Publication). Apixaban: Drug Overview and Analysis. [Market Research Report - specific title and publisher if known]. [5] IQVIA. (Year of Publication). Anticoagulant Market Analysis. [Market Research Report - specific title and publisher if known]. [6] U.S. Patent and Trademark Office. (n.d.). Patent Databases. Retrieved from https://www.uspto.gov/ [7] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/ [8] Japan Patent Office. (n.d.). J-PlatPat. Retrieved from [Specific URL if available]. [9] EvaluatePharma. (Year of Publication). Apixaban: Market Forecasts. [Pharma Analytics Report - specific title and publisher if known]. [10] Bloomberg Intelligence. (n.d.). Pharmaceutical Sector Reports. [Internal or subscription-based reports].